{"id":"NCT00595465","sponsor":"Valneva Austria GmbH","briefTitle":"Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51","officialTitle":"Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-02","completion":"2008-06","firstPosted":"2008-01-16","resultsPosted":"2012-11-20","lastUpdate":"2014-05-16"},"enrollment":389,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"Japanese Encephalitis purified inactivated vaccine","otherNames":[]}],"arms":[{"label":"IC51 Batch A","type":"ACTIVE_COMPARATOR"},{"label":"IC51 Batch B","type":"ACTIVE_COMPARATOR"},{"label":"IC51 Batch C","type":"ACTIVE_COMPARATOR"}],"summary":"The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody","timeFrame":"Day 56","effectByArm":[{"arm":"IC51 Batch IC51/07E/006A","deltaMin":160.8,"sd":398},{"arm":"IC51 Batch IC51/07E/007A","deltaMin":188.2,"sd":410.2},{"arm":"IC51 Batch IC51/07E/008A","deltaMin":168.4,"sd":483.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":4,"countries":["Austria","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":130},"commonTop":["Headache","Influenza Like Illness","Fatigue","Myalgia","Nausea"]}}